ADRB1 and neoplasm: They reported that deletion of ADRB1 in T cells, or pharmacological blockade of ADRB1 using β-blockers (BBs), enhanced the secretion of effector molecules and cytokines and improved T cell function in chronic infection and tumor settings (8).